Pruritus Therapeutics Market Share, Growth & Forecast [2030]

Pruritus Therapeutics Market Share, Growth & Forecast [2030]

Segments - Pruritus Therapeutics Market by Types (Allergic Contact Dermatitis, Urticaria, Atopic Dermatitis, and Others), Products (Local Anesthetics, Corticosteroids, Antihistamines, Counterirritants, Calcineurin Inhibitors, Immunosuppressant, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vineet
Fact-checked by : Vineet Pandey
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-2506 | 4.1 Rating | 70 Reviews | 195 Pages | Format : PDF Excel PPT

Report Description


The global pruritus therapeutics market size is projected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing cases of pruritus condition such as urticarial, psoriasis, and atopic dermatitis, and introduction of new products launched by key pharmaceutical companies.

Pruritus Therapeutics Market summary

Pruritus refers to itch disorder that can be caused by several ailments ranging from dermatological disorders such as atopic dermatitis, mycoses, contact dermatitis, and chickenpox. Moreover, the dermatologic and systemic causes of pruritus are interlinked. A key dermatologic syndrome is usually diagnosed by a typical itching.

Cholestatic pruritus, renal pruritus, hematologic pruritus, malignancy-associated pruritus, endocrine pruritus, and idiopathic generalized pruritus are all skin diseases associated with pruritus condition. People with chronic renal failure may experience renal pruritus. Furthermore, pruritic patients' skin contains higher quantities of ions such calcium, phosphate, and magnesium. Scratching produces secondary skin disorders such as dryness, infection, excoriation, and contact allergy when severe pruritus is present.


However, chronic pruritus affects people's capacity to function as well as causing mood swings, disrupted sleep patterns, high levels of anxiety leading to despair, and a lower overall quality of life. As a result, industry participants are developing new medications and treatments to help people with persistent skin problems.

Due to the COVID-19 pandemic outbreak, the pruritus market is substantially impacted. However, all major precautions are taken to treat pruritus condition, followed by prescribed guidelines. Alternatively, patients are encouraged telemedicine consultation for follow-ups, and hospitals & clinics are minimizing the contact between patients & staff for the treatment.

  • Rising cases of dermatological disease influencing the occurrence of pruritus and increasing demand for efficient diagnostics are fueling the market growth in the coming years.
  • Increasing development strategies for new drugs for the treatment and robust pipeline products are expected to propel the market growth.
  • Lack of understanding of disease pathophysiology and side effects of drugs are some of the major restraining factors hindering the market growth.
  • Unavailability of advanced alternatives with better efficacy to treat pruritus is another key factor hampering the market growth.
  • Growing research funding by emerging players and favorable regulatory policies for external drugs are expected to offer great opportunity for market expansion in the near future.

Scope of the Report

The report on the global pruritus therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Pruritus Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Types (Allergic Contact Dermatitis, Urticaria, Atopic Dermatitis, and Others) and Products (Local Anesthetics, Corticosteroids, Antihistamines, Counterirritants, Calcineurin Inhibitors, Immunosuppressant, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Uloric; Cara Therapeutics; UCB Pharma; Sanofi Aventisand; Actavis Plc; and Pfizer, Inc.

Market Segment Insights

Allergic contact segment is expected to grow at a robust pace

Based on types, the global pruritus therapeutics market is segmented into allergic contact dermatitis, urticaria, atopic dermatitis, and others. The allergic contact segment is expected to grow at a robust pace during the forecast period. It is the third most prevalent reason for patients to take advice from dermatologist. Furthermore, the growing popularity of ear, navel, and nose piercing, allergic contact dermatitis is becoming more common in women.

As per reports, nickel allergies affect around 20% to 40% of women. In the US, the prevalence of contact dermatitis ranges from 1.5% to 5.4% and it accounts for 95% of all reported occupational skin diseases. Thus, it is expected to boost the segment growth in the coming years.

Pruritus Therapeutics Market type

Corticosteroids segment is projected to expand at a considerable CAGR

On the basis of products, the market is segregated as local anesthetics, corticosteroids, antihistamines, counterirritants, calcineurin inhibitors, immunosuppressant, and others. The corticosteroids segment is projected to expand at a considerable CAGR during the forecast period. The growth of the segment is attributed to the wide usage of the products to provide relief from atopic dermatitis or psoriasis and increasing demand for over the counter topical corticosteroids. Furthermore, corticosteroids are mostly used as the first line of treatment products associated with pruritus condition.

Moreover, corticosteroids are used to treat skin disorders as they reduce the amount of collagen produced in the skin that further diminishes inflammation. It comes in topical forms such as lotions, ointments, shampoos, creams, mousses, gels and tapes that can be applied to the skin. Furthermore, rashes can be effectively treated with a range of corticosteroids and other anti-inflammatory lotions that can be applied to the skin. Thus, it is estimated to upsurge the segment growth.

North America is anticipated to constitute a key market share

In terms of regions, the global pruritus therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period owing to the presence of favorable government initiatives, introduction of new products, rising prevalence of target diseases, and the presence of pruritus encouraging climate condition in the region.

Pruritus Therapeutics Market region

 

Segments

Segments Covered in the Report

The global pruritus therapeutics market has been segmented on the basis of

Types

  • Allergic Contact Dermatitis
  • Urticaria
  • Atopic Dermatitis
  • Others

Products

  • Local Anesthetics
  • Corticosteroids
  • Antihistamines
  • Counterirritants
  • Calcineurin Inhibitors
  • Immunosuppressant
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Uloric
  • Cara Therapeutics
  • UCB Pharma
  • Sanofi Aventisand
  • Actavis Plc
  • Pfizer, Inc.

Competitive Landscape

Some of the key players competing in the global pruritus therapeutics market are Uloric; Cara Therapeutics; UCB Pharma; Sanofi Aventisand; Actavis Plc; and Pfizer, Inc. These companies are implementing strategies such as technological advancements, innovative solution, new developed product launches, research initiatives, merger & acquisitions, and regional expansions to secure their advantageous position in the pruritus therapeutics market.

For instance, in August 2020, MC2 Therapeutics, a Europe-based company entered into a partnership with EPI Health, LLC to market its Wynzora Cream in the US. Furthermore, MC2 Therapeutics has received Wynzora’s United States Food and Drug Administration (USFDA) approval for the treatment of plaque psoriasis in adults in July 2020.

Cara Therapeutics, a clinical-stage biopharmaceutical company, has announced the successful completion of its Phase-II dose-ranging trial of oral Korsuva for moderate to severe chronic kidney disease associated with pruritus in June 2020. On the other hand, Menlo Therapeutics Inc. has publicized the top-line results from two recent Phase-III clinical trials investigating the accuracy and safety of oral serlopitant for the cure of pruritus associated with prurigo nodularis in April 2020.

Pruritus Therapeutics Market keyplayers

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pruritus Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Pruritus Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Pruritus Therapeutics Market - Supply Chain
  4.5. Global Pruritus Therapeutics Market Forecast
     4.5.1. Pruritus Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Pruritus Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Pruritus Therapeutics Market Absolute $ Opportunity
5. Global Pruritus Therapeutics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Pruritus Therapeutics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Pruritus Therapeutics Demand Share Forecast, 2019-2026
6. North America Pruritus Therapeutics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Pruritus Therapeutics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Pruritus Therapeutics Demand Share Forecast, 2019-2026
7. Latin America Pruritus Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Pruritus Therapeutics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Pruritus Therapeutics Demand Share Forecast, 2019-2026
8. Europe Pruritus Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Pruritus Therapeutics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Pruritus Therapeutics Demand Share Forecast, 2019-2026
9. Asia Pacific Pruritus Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Pruritus Therapeutics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Pruritus Therapeutics Demand Share Forecast, 2019-2026
10. Middle East & Africa Pruritus Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Pruritus Therapeutics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Pruritus Therapeutics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Pruritus Therapeutics Market: Market Share Analysis
  11.2. Pruritus Therapeutics Distributors and Customers
  11.3. Pruritus Therapeutics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Uloric
     11.4.2. Cara Therapeutics
     11.4.3. UCB Pharma
     11.4.4. Sanofi Aventisand
     11.4.5. Actavis Plc
     11.4.6. Pfizer, Inc.

Methodology

Our Clients

General Mills
Pfizer
Dassault Aviation
Honda Motor Co. Ltd.
General Electric
Nestle SA
FedEx Logistics
Siemens Healthcare